177Lu-PSMA radio-ligand therapy

被引：1

作者：

Chanchou, M. ^{[1
]}

Giraudet, A. L. ^{[2
]}

机构：

[1] UCA, Serv Med Nucl,Inserm, Ctr Jean Perrin, UMR 1240,IMoST, 58 Rue Montalembert, F-63011 Clermont Ferrand, France

[2] Ctr Leon Berard, Serv Med Nucl, Lyon, France

来源：

MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE | 2023年 / 47卷 / 06期

关键词：

Lu-177-PSMA; RLT; PSMA-PET; MCRPC; RESISTANT PROSTATE-CANCER; TRIAL;

D O I：

10.1016/j.mednuc.2023.09.005

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Lutetium-177-labeled PSMA radio-ligand therapy is becoming more and more widespread in nuclear medicine departments, in France and around the world. Practitioners must master specificities of this treatment in order to develop this type of therapeutic care in the best conditions. This summary article presents the methods of carrying out treatment with Lu-177-PSMA in nuclear medicine departments as well as the various current clinical research subjects concerning this theme. (C) 2023 Elsevier Masson SAS. All rights reserved.

引用

页码：316 / 322

页数：7

共 21 条

[1] PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, 2 trial [J].

Buteau, James P. ;

Martin, Andrew J. ;

Emmett, Louise ;

Iravani, Amir ;

Sandhu, Shahneen ;

Joshua, Anthony M. ;

Francis, Roslyn J. ;

Zhang, Alison Y. ;

Scott, Andrew M. ;

Lee, Sze-Ting ;

Azad, Arun A. ;

McJannett, Margaret M. ;

Stockler, Martin R. ;

Williams, Scott G. ;

Davis, Ian ;

Hofman, Michael S. .

LANCET ONCOLOGY, 2022, 23 (11) :1389-1397

[2] Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer [J].

Fanti, Stefano ;

Goffin, Karolien ;

Hadaschik, Boris A. ;

Herrmann, Ken ;

Maurer, Tobias ;

MacLennan, Steven ;

Oprea-Lager, Daniela E. ;

Oyen, Wim J. G. ;

Rouviere, Olivier ;

Mottet, Nicolas ;

Bjartell, Anders .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (02) :469-476

[3] PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0 [J].

Fendler, Wolfgang P. ;

Eiber, Matthias ;

Beheshti, Mohsen ;

Bomanji, Jamshed ;

Calais, Jeremie ;

Ceci, Francesco ;

Cho, Steve Y. ;

Fanti, Stefano ;

Giesel, Frederik L. ;

Goffin, Karolien ;

Haberkorn, Uwe ;

Jacene, Heather ;

Koo, Phillip J. ;

Kopka, Klaus ;

Krause, Bernd J. ;

Lindenberg, Liza ;

Marcus, Charles ;

Mottaghy, Felix M. ;

Oprea-Lager, Daniela E. ;

Osborne, Joseph R. ;

Piert, Morand ;

Rowe, Steven P. ;

Schoeder, Heiko ;

Wan, Simon ;

Wester, Hans-Jurgen ;

Hope, Thomas A. ;

Herrmann, Ken .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (05) :1466-1486

[4] Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria [J].

Gafita, Andrei ;

Rauscher, Isabel ;

Fendler, Wolfgang P. ;

Murthy, Vishnu ;

Hui, Wang ;

Armstrong, Wesley R. ;

Herrmann, Ken ;

Weber, Wolfgang A. ;

Calais, Jeremie ;

Eiber, Matthias ;

Weber, Manuel ;

Benz, Matthias R. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (12) :4271-4281

[5] Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study [J].

Gafita, Andrei ;

Rauscher, Isabel ;

Weber, Manuel ;

Hadaschik, Boris ;

Wang, Hui ;

Armstrong, Wesley R. ;

Tauber, Robert ;

Grogan, Tristan R. ;

Czernin, Johannes ;

Rettig, Matthew B. ;

Herrmann, Ken ;

Calais, Jeremie ;

Weber, Wolfgang A. ;

Benz, Matthias R. ;

Fendler, Wolfgang P. ;

Eiber, Matthias .

JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (11) :1651-1658

[6] Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study [J].

Gafita, Andrei ;

Calais, Jeremie ;

Grogan, Tristan R. ;

Hadaschik, Boris ;

Wang, Hui ;

Weber, Manuel ;

Sandhu, Shahneen ;

Kratochwil, Clemens ;

Esfandiari, Rouzbeh ;

Tauber, Robert ;

Zeldin, Anna ;

Rathke, Hendrik ;

Armstrong, Wesley R. ;

Robertson, Andrew ;

Thin, Pan ;

D'Alessandria, Calogero ;

Rettig, Matthew B. ;

Delpassand, Ebrahim S. ;

Haberkorn, Uwe ;

Elashoff, David ;

Herrmann, Ken ;

Czernin, Johannes ;

Hofman, Michael S. ;

Fendler, Wolfgang P. ;

Eiber, Matthias .

LANCET ONCOLOGY, 2021, 22 (08) :1115-1125

[7] Early Prostate-Specific Antigen Changes and Clinical Outcome After 177Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer [J].

Gafita, Andrei ;

Heck, Matthias M. ;

Rauscher, Isabel ;

Tauber, Robert ;

Cala, Lisena ;

Franz, Charlott ;

D'Alessandria, Calogero ;

Retz, Margitta ;

Weber, Wolfgang A. ;

Eiber, Matthias .

JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (10) :1476-1483

[8] A review of recent advancements in Actinium-225 labeled compounds and biomolecules for therapeutic purposes [J].

Hassan, Maria ;

Bokhari, Tanveer Hussain ;

Lodhi, Nadeem Ahmed ;

Khosa, Muhammad Kaleem ;

Usman, Muhammad .

CHEMICAL BIOLOGY & DRUG DESIGN, 2023, 102 (05) :1276-1292

[9] TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603) [J].

Hofman, Michael S. ;

Emmett, Louise ;

Violet, John ;

Zhang, Alison Y. ;

Lawrence, Nicola J. ;

Stockler, Martin ;

Francis, Roslyn J. ;

Iravani, Amir ;

Williams, Scott ;

Azad, Arun ;

Martin, Andrew ;

McJannett, Margaret ;

Davis, Ian D. .

BJU INTERNATIONAL, 2019, 124 :5-13

[10] Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors [J].

Jackson, Price A. ;

Hofman, Michael S. ;

Hicks, Rodney J. ;

Scalzo, Mark ;

Violet, John .

JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (07) :1030-1036

← 1 2 3 →